Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 261-283

  Soh, Jae Won ^a   Weinstein, I Bernard ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; ANTINEOPLASTIC AGENT; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CHUK PROTEIN, HUMAN; CYCLIC GMP PHOSPHODIESTERASE; ENZYME INHIBITOR; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PDE2 PHOSPHODIESTERASE; PHOSPHODIESTERASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; NEOPLASM; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; NF-KAPPA B; PHOSPHORIC DIESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 0042632585     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071377     Document Type: Article

References (110)

1. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002;94:252-266.
2. Baron JA, Sandler RS: Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-523.
3. Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, Beer DG: Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2000;2:346-356.
4. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, Rumpler G, Landthaler M, Stolz W: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001;11:587-599.
5. Smith ML, Hawcroft G, Hull MA: The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action. Eur J Cancer 2000;36: 664-674.
6. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-245.
7. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-2033.
8. Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti- inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-1683.
9. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B: Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001;22:17-25.
10. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-591.
11. Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-459.
12. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-6051.
13. Chiu CH, McEntee ME Whelan J: Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-4273.
14. Weber A, Yildirim H, Schror K: Cyclooxygenase-independent inhibition of smooth muscle cell mitogenesis by ibuprofen. Eur J Pharmacol 2000;389:67-69.
15. McCracken JD, Wechter WJ, Liu Y, Chase RL, Kantoci D, Murray ED Jr, Quiggle DD, Mineyama Y: Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol 1996; 36:540-545.
16. Wechter WJ, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, McCracken JD: R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: Implications for prophylaxis and treatment of colon cancer. Cancer Res 1997;57: 4316-4324.
17. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, Greenberg NM: E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-2208.
18. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, Wallace JL: Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998;62:PL367-373.
19. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999;58:1097-1107.
20. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA: Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999;53:440-445.
21. Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N: Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2000;60:2085-2089.
22. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-2915.
23. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res 1997;57:2452-2459.
24. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-3116.
25. Rybalkin SD, Beavo JA: Multiplicity within cyclic nucleotide phosphodiesterases. Biochem Soc Trans 1996;24:1005-1009.
26. Perry MJ, Higgs GA: Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 1998;2:472-481.
27. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000;60:3338-3342.
28. Park K, Moreland RB, Goldstein I, Atala A, Traish A: Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998;249:612-617.
29. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I: A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 1995; 272:825-831.
30. Soh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB: Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase I. Clin Cancer Res 2000;6:4136-4141.
31. Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB: Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem 2001;276:16406-16410.
32. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S: Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Racl. J Biol Chem 1997;272:25238-25242.
33. Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
34. Loweth AC, Williams GT, Scarpello JH, Morgan NG: Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett 1997;400:285-288.
35. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J, Walter U: cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein in vitro and in intact human platelets. J Biol Chem 1994;269:14509-14517.
36. Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB: VASP phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002;1(in press).
37. Butt E, Immler D, Meyer HE, Kotlyarov A, Laass K, Gaestel M: Heat-shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: Phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 2001;276:7108-7113.
38. Ammendola A, Geiselhoringer A, Hofmann F, Schlossmann J: Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate and cGMP kinase Iβ. J Biol Chem 2001;276:24153-24159.
39. Huber A, Neuhuber WL, Klugbauer N, Ruth P, Allescher HD: Cysteine-rich protein 2, a novel Substrate for cGMP kinase I in enteric neurons and intestinal smooth muscle. J Biol Chem 2000; 275:5504-5511.
40. Thomas MK, Francis SH, Corbin JD: Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 1990;265:14971-14978.
41. Murthy KS: Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 2001;360:199-208.
42. Ghosh S, Karin M: Missing pieces in the NF-κB puzzle. Cell 2002; 109(suppl):81-96.
43. Karin M, Cao Y, Greten FR, Li ZW: NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
44. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T: Signal-induced site-specific phosphorylation targets I κB-α to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-1597.
45. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of I κB-α proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485-1488.
46. Baeuerle PA, Baltimore D: NF-κB: Ten years after. Cell 1996;87:13-20.
47. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-27314.
48. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 1998;396:77-80.
49. Belham C, Wu S, Avruch J: Intracellular signalling: PDK1 - a kinase at the hub of things. Curr Biol 1999;9:R93-R96.
50. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer cell line HT-29. J Biol Chem 2002;277:27613-27621.
51. Zhao Y, Bjorbaek C, Moller DE: Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. J Biol Chem 1996;271:29773-29779.
52. Bjorbaek C, Zhao Y, Moller DE: Divergent functional roles for p90rsk kinase domains. J Biol Chem 1995;270:18848-18852.
53. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK: Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-κB-responsive genes. J Immunol 1999;163: 5608-5616.
54. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993;366:643-654.
55. Herrmann C, Block C, Geisen C, Haas K, Weber C, Winde G, Moroy T, Muller O: Sulindac sulfide inhibits Ras signaling. Oncogene 1998;17:1769-1776.
56. Houseknecht KL, Cole BM, Steele PJ: Peroxisome proliferator-activated receptor γ (PPARγ) and its ligands: A review. Dornest Anim Endocrinol 2002;22:1-23.
57. Sporn MB, Suh N, Mangelsdorf DJ: Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol Med 2001;7:395-400.
58. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
59. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN: Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling. Mol Pharmacol 2002;61:7-12.
60. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T: Prostacyclin-dependent apoptosis mediated by PPARδ. J Biol Chem 2001;276:46260-46267.
61. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN: Prostacyclin-mediated activation of peroxisome proliferator-activated receptor-δ in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-13280.
62. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345.
63. Park BH, Vogelstein B, Kinzler KW: Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001;98:2598-2603.
64. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW: Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
65. Barracchini A, Franceschini N, Amicosante G, Oratore A, Minisola G, Pantaleoni G, Di Giulio A: Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J Pharm Pharmacol 1998;50:1417-1423.
66. Seger R, Krebs EG: The MAPK signaling cascade. Faseb J 1995;9:726-735.
67. Schwenger P, Skolnik EY, Vilcek J: Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J Biol Chem 1996;271:8089-8094.
68. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, Weissmann G: Modes of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998;95:14540-14545.
69. Schwenger P, Alpert D, Skolnik EY, Vilcek J: Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J Cell Physiol 1999;179:109-114.
70. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J: Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997; 94:2869-2873.
71. Schwenger P, Alpert D, Skolnik EY, Vilcek J: Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκB-α phosphorylation and degradation. Mol Cell Biol 1998;18:78-84.
72. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000;256:34-41.
73. Hemmings BA: Akt signaling: Linking membrane events to life and death decisions. Science 1997;275:628-630.
74. Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395.
75. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
76. Grammer TC, Cheatham L, Chou MM, Blenis J: The p70S6K signalling pathway: A novel signalling system involved in growth regulation. Cancer Surv 1996;27:271-292.
77. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, Moses HL: Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin Dl, cyclin A, and proliferating cell nuclear antigen. J Biol Chem 2000;275:3826l-38267.
78. Frantz B, O'Neill EA: The effect of sodium salicylate and aspirin on NF-κB. Science 1995;270: 2017-2019.
79. Kopp E, Ghosh S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265: 956-959.
80. McDade TP, Perugini RA, Vittimberga FJ Jr, Carrigan RC, Callery MP: Salicylates inhibit NF-κB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999;83:56-61.
81. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T: Salicylates inhibit I κB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996;156:3961-3969.
82. Tegeder I, Niederberger E, Israr E, Guhring H, Brune K, Euchenhofer C, Grosch S, Geisslinger G: Inhibition of NF-κB and AP-1 activation by R- and S-flurbiprofen. Faseb J 2001;15:2-4.
83. Stuhlmeier KM, Li H, Kao JJ: Ibuprofen: New explanation for an old phenomenon. Biochem Pharmacol 1999;57:313-320.
84. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD: Constitutive activation of IκB kinase-α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394.
85. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G: Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB. Faseb J 2001;15:1622-1624.
86. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400.
87. Dong Z, Huang C, Brown RE, Ma WY: Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997;272:9962-9970.
88. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z: Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997;272:26325-26331.
89. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-6850.
90. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM: 15-LOX-1 : A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000;92:1136-1142.
91. Chao DT, Korsmeyer SJ: BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998;16: 395-419.
92. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE: Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-908.
93. Baek SJ, Wilson LC, Lee CH, Eling TE: Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002;301:1126-1131.
94. Kang HJ, Song MJ, Choung SY, Kim SJ, Le MO: Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull 2000;23: 815-819.
95. Liu ZG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA: Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 1994;367:281-284.
96. Woronicz JD, Calnan B, Ngo V, Winoto A: Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature 1994;367:277-281.
97. Polakis P, Hart M, Rubinfeld B: Defects in the regulation of β-catenin in colorectal cancer. Adv Exp Med Biol 1999;470:23-32.
98. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM: Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998;124:225-231.
99. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G: COX-2-independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 2001;15:2742-2744.
100. Subbegowda R, Frommel TO: Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res 1998;58:2772-2776.
101. Perugini RA, McDade TP, Vittimberga FJ Jr, Duffy AJ, Callery MP: Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 2000;4:24-33.
102. Marra DE, Simoncini T, Liao JK: Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Wafl) and p27(Kipl). Circulation 2000;102: 2124-2130.
103. Shiff SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
104. Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA, Xing WQ, Weinstein IB: Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 1998;48:195-203.
105. Ikui AE, Yao Y, Zhou P, Weinstein IB: Induction of apoptosis by sulindac sulfide in HL60 cells is enhanced by p21CiP1 or p27KiP1. Anticancer Res 2001;21:2297-2303.
106. Yoon JT, Palazzo AF, Xiao D, Delohery TM, Warburton PE, Bruce JN, Thompson WJ, Sperl G, Whitehead C, Fetter J, Pamukcu R, Gundersen GG, Weinstein IB: CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther 2002;1:393-404.
107. Duggan DE, Hooke KF, Hwang SS: Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab Dispos 1980;8:241-246.
108. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 1989;157:175-179.
109. Bhujwalla ZM, Artemov D, Aboagye E, Ackerstaff E, Gillies RJ, Natatajan K, Solaiyappan M: The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found Symp 2001;240:23-38.
110. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science 2000;290:989-992.